At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 178 enrolled
Drug / intervention
Tislelizumab +1 morebiological
Likely dose
Tislelizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previously Treated Recurrent or Metastatic Cervical Cancer
In Brief
A Phase 2 clinical trial evaluating Tislelizumab and Ociperlimab for Cervical Cancer. Completed, enrolled 178 participants across 68 sites in 8 countries.
Detailed Summary
This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous treatments. The study included two groups and took place at multiple medical centers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesBulgaria, China, Poland, Russia, South Korea, Taiwan, Thailand, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartFeb 2021
Primary CompletionJun 2022
Study CompletionAug 2023
TodayJul 2026
First PostedJan 5, 2021
Enrollment StartFeb 15, 2021
Primary CompletionJun 16, 2022
Study CompletionAug 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.5 years ago
Interventions
Tislelizumabbiological
200 mg administered intravenously once every 3 weeks on day 1 of each cycle
Ociperlimabbiological
900 mg administered intravenously once every 3 weeks on day 1 of each cycle